AFT Leaves X Over AI-Generated Images of Minors 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
MALVERN, Pa., March 29, 2017 -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biopolymer-based drugs for the treatment of orphan diseases with an initial focus on cardiopulmonary disorders, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at Needham & Company’s 16th Annual Healthcare Conference on Wednesday, April 5, at 11:40 a.m. EDT at The Westin New York Grand Central in New York City.
For additional information on the conference, please visit:
http://www.needhamco.com/Default/InstitutionalSalesAndTrading/Conferences.aspx.
About PhaseBio
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing new and improved biotherapeutics for the treatment of orphan diseases, with a focus on cardiopulmonary disorders. The company’s proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which can lead to less-frequent dosing and better patient compliance. PhaseBio's lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension (PAH); the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy; and the treatment of cystic fibrosis. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Media Contact: Laura Bagby, 6 Degrees (312) 448-8098 [email protected]
